Characterization of the Murine K14-FynY528F Transgenic SCC Model Provides Novel Therapeutic Insights
Michael D Gober and John T Seykora*
Perelman School of Medicine at the University of Pennsylvania, Department of Dermatology Biomedical Research Building, Philadelphia PA 19104, USA
- *Corresponding Author:
- John T. Seykora
Departments of Dermatology and Pathology
Member CAMB Graduate Group
Member Abramson Cancer Center
Perelman School of Medicine at the University of Pennsylvania
Room 1011 BRB II/III, 421 Curie Blvd.Philadelphia, PA 19104, USA
Tel: 215-898- 0170
E-mail: [email protected]
Received date: January 22, 2015; Accepted date: April 09, 2015; Published date: April 11, 2015
Citation: Gober MD, Seykora JT (2015) Characterization of the Murine K14- FynY528F Transgenic SCC Model Provides Novel Therapeutic Insights. Med chem 5:149-151. doi:10.4172/2161-0444.1000256
Copyright: ©2015 Gober MD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cutaneous squamous cell carcinoma (cSCC) is one of the most common human malignancies. The development of mouse models that accurately recapitulate the human condition is crucial for testing novel therapeutic modalities. In this article we discuss the utility of the K14-Fyn-Y528F transgenic mouse as a model for cSCC and actinic keratosis like precursor lesions and its use in testing novel small molecule kinase inhibitorstopically.